Glecaprevir/Pibrentasvir · more major-labeled pairs than Buprenorphine/Naloxone
SPL labels Glecaprevir/Pibrentasvir + Buprenorphine/Naloxone as minor; Glecaprevir/Pibrentasvir 26 / Buprenorphine/Naloxone 19 in that band.
Mechanism on file: These medications do not interfere with each other's levels in the blood or how they work in the body.
FDA SPL severity: Minor
Glecaprevir/Pibrentasvir + Buprenorphine/Naloxone · SPL mechanism field
These medications do not interfere with each other's levels in the blood or how they work in the body.
Minor band excerpt · Glecaprevir/Pibrentasvir with Buprenorphine/Naloxone
↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET.
Glecaprevir/Pibrentasvir · 3 major-labeled pairs (vs Buprenorphine/Naloxone's 0)
- Amlodipine minor
- Atorvastatin minor
- Buprenorphine minor
- Carbamazepine minor
Buprenorphine/Naloxone · 19 minor + 19 total pairs
- Buprenorphine minor
- Carbamazepine minor
- Cyclobenzaprine minor
- Darunavir minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.